POWER 3 MEDICAL PRODUCTS INC Files SEC form 10-Q, Quarterly Report

ITEM 2- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This report contains "forward-looking statements". All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. "Forward-looking statements" may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our "forward-looking statements" are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any "forward-looking statements", are subject to change and to inherent risks and uncertainties, such as those disclosed in this report. In light of the significant uncertainties inherent in the "forward-looking statements" included in this report, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Except for its ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any "forward-looking statement". Accordingly, the reader should not rely on "forward-looking statements", because they are subject to known and unknow...
Click here to read the whole Article (external link)

Emerging Stock Report Initiates Independent Research Coverage On Power3 Medical Products, Inc.

Emerging Stock Report Initiates Independent Research Coverage On Power3 Medical Products, Inc. - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bott...
Click here to read the whole Article (external link)

Power3 Medical Products, Inc. Headlines Session at International Molecular Diagnostic Meeting in China

HOUSTON--(BUSINESS WIRE)--Power3 Medical Products, Inc. (OTCBB: PWRM - News2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is “New Leadership of Personalized Medicine.” In his Keynote address, entitled “Principles of Omic Medicine Applied to Differential Diagnosis - Breast Cancer and Neurodegenerative Diseases,” Dr. Goldknopf will discuss the “necessary fundamental principles” that BC-SeraPro™ and NuroPro® exemplify which enable the company’s biomarkers and tests to “more effectively address the unmet clinical needs that challenge us today.” He will describe the company’s unique position and ability to use biomarkers for testing in personalized medicine and the various facets that are required for discovery, validation and to commercialize a group of biomarkers.Biochemical and Biophysical Research Communications (Reuters Sept. 2, 2009), and more publications are in the works.”“We are extremely proud and excited about the recognition of Dr. Goldknopf and Power3 by the opportunity to chair this session and present at this international meeting,” said Ms. Helen Park, Power3’s CEO. “Dr. Goldknopf is the Keynote speaker and will feature new progress in clinical validation of the company’s biomar...
Click here to read the whole Article (external link)

Power3 Medical Products Inc. CEO Interview: Helen R. Park

67 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies - Biology R & D - Lab Services Business Model - International Economic Exposure - Effect of Recession on Sector Stocks - Top Stock Winners and Losers in Medical Research Services - Top Stock Winners and Losers in Medical Diagnostics Companies include: Arrowhead Research (ARWR); Cleveland BioLabs (CBLI); IR BioSciences Holdings (IRBS); Power3 Medical Products (PWRM); Illumina (ILMN); Luminex (LMNX); Waters (WAT); Life Technologies (LIFE); QIAGEN (QGEN); Sangamo BioSciences (SGMO); Beckman Coulter (BEC); Invitrogen (IVGN); Amgen (AMGN); Bristol-Myers (BMY); Eli Lilly & Co. (LLY); Myriad Genetics (MYGN); Genomic Health (GHDX); Targeted Genetics (TGEN); Dow Chemical (DOW); Sigma-Aldrich (SIAL); MDS (MDZ); Danaher (DHR); Cepheid (CPHD); Inverness Medical Innovations (IMA); Quidel (QDEL); Meridian Bioscience (VIVO); Gen-Probe (GPRO); Sequenom (SQNM); Genoptix (GXDX); Response Genetics (RGDX); Affymetrix (AFFX); Monogram Bioscience (MGRN); LabCorp (LH) In the following brief excerpt from the 23 page report, Helen R....
Click here to read the whole Article (external link)

Arrowhead Research Corp. CEO and President Interview: Christopher Anzalone

67 WALL STREET, New York - September 15, 2009 - The Wall Street Transcript has just published its Medical Research Services report offering a timely review of the sector to serious investors and industry executives. This 23 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online. Topics covered: Medical Device Research Services - Pharmaceutical Research Services - Diagnostics - Life Science Research Supplies - Biology R & D - Lab Services Business Model - International Economic Exposure - Effect of Recession on Sector Stocks - Top Stock Winners and Losers in Medical Research Services - Top Stock Winners and Losers in Medical Diagnostics Companies include: Arrowhead Research (ARWR); Cleveland BioLabs (CBLI); IR BioSciences Holdings (IRBS); Power3 Medical Products (PWRM); Illumina (ILMN); Luminex (LMNX); Waters (WAT); Life Technologies (LIFE); QIAGEN (QGEN); Sangamo BioSciences (SGMO); Beckman Coulter (BEC); Invitrogen (IVGN); Amgen (AMGN); Bristol-Myers (BMY); Eli Lilly & Co. (LLY); Myriad Genetics (MYGN); Genomic Health (GHDX); Targeted Genetics (TGEN); Dow Chemical (DOW); Sigma-Aldrich (SIAL); MDS (MDZ); Danaher (DHR); Cepheid (CPHD); Inverness Medical Innovations (IMA); Quidel (QDEL); Meridian Bioscience (VIVO); Gen-Probe (GPRO); Sequenom (SQNM); Genoptix (GXDX); Response Genetics (RGDX); Affymetrix (AFFX); Monogram Bioscience (MGRN); LabCorp (LH) In the following brief excerpt from the 23 page report, Christoph...
Click here to read the whole Article (external link)

POWER 3 MEDICAL PRODUCTS INC Financials

PERIOD ENDING30-Jun-0931-Mar-0931-Dec-0830-Sep-08Total Revenue36  133  1   -  Cost of Revenue -   -   -   -  Gross Profit36  133  1   -  Operating ExpensesResearch Development -   -   -   -  Selling General and Administrative850  202  1,449  406  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(815)(69)(1,448)(406)Income from Continuing OperationsTotal Other Income/Expenses Net465  (1,630)844  1,619  Earnings Before Interest And Taxes(349)(1,699)(605)1,213  Interest Expense138  177  563  394  Income Before Tax(487)(1,876)(1,168)819  Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(487)(1,876)(1,168)819  Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes -   -   ...
Click here to read the whole Article (external link)

InvestorSoup.com Issues Technical Trading Overview for Power3 Medical Products Inc.

DALLAS, Aug. 27, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Power3 Medical Products Inc. (OTCBB:PWRM - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision. The investment report on Power3 Medical Products Inc. (OTCBB:PWRM - News) should be of particular interest to companies engaged in medical research: Encorium Group Inc. (Nasdaq:ENCO - News), Health Discovery Corp. (OTCBB:HDVY - News), Neurologix, In...
Click here to read the whole Article (external link)

Power3 Medical Products, Inc. Files for 3 Patents On Blood Test for Diagnosis of Early Stage Breast Cancer

THE WOODLANDS, Texas, Aug. 20, 2009 (GLOBE NEWSWIRE) -- Power3 Medical Products, Inc. (OTCBB:PWRM - News), (www.power3medical.com), announced today that the company made significant advances in the technology for their BC-SeraPro serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications. "Roughly 200,000 women in the US and 1.2 million women worldwide are diagnosed with breast cancer each year. In the US, roughly 40,000 women die of the disease because the cancer is caught too late. In fact, nearly 1/2 of all cancers are missed as false negatives, and 75% of the biopsies of suspected breast cancer performed are false positive and therefore could have been avoided if there was a more accurate test that could be made readily available," said Ira L. Goldknopf, Ph.D., president and chief scientific officer of Power3. "We now have made strides towards this goal through refinements in our blood test for early stage detection of breast cancer." As disclosed in the patent applications, Power3 has identified a group of 22 blood serum proteins with abnormal concentrations in women with breast cancer. Using the company's BC-SeraPro platform, Power3 used these protein biomarkers to distinguish women with breast cancer from those...
Click here to read the whole Article (external link)

POWER 3 MEDICAL PRODUCTS INC Files SEC form 10-Q, Quarterly Report

ITEM 2- MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This report contains "forward-looking statements". All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. "Forward-looking statements" may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our "forward-looking statements" are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any "forward-looking statements", are subject to change and to inherent risks and uncertainties, such as those disclosed in this report. In light of the significant uncertainties inherent in the "forward-looking statements" included in this report, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved. Except for its ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any "forward-looking statement". Accordingly, the reader should not rely on "forward-looking statements", because they are subject to known and unknow...
Click here to read the whole Article (external link)